AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 2026 -- The trial uses a response-driven dosing strategy and extended treatment across three prostate cancer populations, supported by the favorable clinical, pharmacokinetic and dosimetry results from Phase 1b -- BRISBANE, Australia & BOSTON--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Anna J.
Contact Anna J., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack